This post was originally published on this site A young woman weeped. Pretty blond hair swung in front of her face, but it didn’t hide her angst. From where I sat, I could feel the panic running though her body. It cut through the room like a chilly, wet breeze and crept into my lungs.…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Agency Unveils RaDaR to Help Patient Groups Develop Rare Disease Registries
This post was originally published on this site RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows
This post was originally published on this site Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of Clovis Oncology‘s ARIEL3 Phase 3 clinical trial found. The data were presented recently at the International Society…
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
This post was originally published on this site Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory multiple myeloma. Ygalo is a lipophilic peptide-conjugated alkylator that works by rapidly delivering a cancer-killing agent (an alkylating…
Trial Testing EDV Nanocells in Pancreatic, Other EGFR-positive Advanced Solid Cancers Now Dosing Patients
This post was originally published on this site A Phase 1/2 clinical trial has started dosing participants to test EnGeneIC‘s second-generation cytotoxic-loaded EDV nanocells as a treatment for EGFR-positive solid cancers who have exhausted all other therapeutic alternatives. The Carolyn Trial (ACTRN12619000385145), still recruiting participants at the Frankston Private Hospital in Victoria, Australia, is expected to…
Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 trial shows. Checkpoint blockade immunotherapies are based on the principle of removing the “brakes” of our immune…
Prostate Cancer Foundation Puts Patients on Path to Knowledge with Updated Guide, Resources
This post was originally published on this site The Prostate Cancer Foundation (PCF) has released its comprehensive Prostate Cancer Patient Guide with the latest in diagnosis, research, treatments, and lifestyle factors for patients and caregivers. With contributions from leading physicians and scientists, the free guide is aimed at patients who have recently been diagnosed, are…
IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas
This post was originally published on this site IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two clinical trials in China, IBI301’s co-developers, Innovent Biologics and Eli Lilly, has announced. “The results of clinical…
Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows
This post was originally published on this site Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. The benefits were seen independently of patients’ initial PSA levels, suggesting that, contrary to prior beliefs, PSA…
Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates
This post was originally published on this site Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from a Phase 1/2 clinical trial. In addition, initial data from a Phase 1 trial also…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
This post was originally published on this site The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma patients not eligible for a stem cell transplant or thalidomide therapy. “This decision is fantastic news for the myeloma patients who will be able to access…
Japanese Researchers Use Hyperion Imaging Tool to Advance Treatment Discovery for Colorectal Cancer
This post was originally published on this site The National Cancer Center (NCC) in Japan is advancing its research into novel immunotherapies for colorectal cancer by using the Hyperion Imaging System, a powerful tool that enables simultaneous visualization of dozens of markers in a sample of tissue. The system, by Fluidigm, combines CyTOF technology with…